News | Prostate Cancer | December 19, 2017

BIO 300 from Humanetics Corp. under development as adjunct therapy in combination with radiation therapy for prevention of radiation-induced erectile dysfunction in prostate cancer patients

New Data Examines Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients

December 19, 2017 — Humanetics Corp. presented data at the annual meetings of the American Society for Radiation Oncology (ASTRO) and the Radiation Research Society (RRS), on the company’s new drug candidate, BIO 300, which is being evaluated as a potential treatment to prevent erectile dysfunction in patients undergoing radiotherapy for prostate cancer. The annual ASTRO meeting was held Sept. 24-27 in San Diego, and the annual RRS meeting was held Oct. 15-18 in Cancun, Mexico; Zeljko Vujaskovic, M.D., Ph.D., a professor of radiation oncology at the University of Maryland School of Medicine (UMSOM) and director of the school’s Division of Translational Radiation Sciences, and Michael Kaytor, Ph.D., vice president of research and development at Humanetics, presented data at the respective meetings.

Prostate cancer is the most common non-skin cancer affecting men in the U.S. According to the National Cancer Institute (NCI), nearly 162,000 men will be diagnosed with prostate cancer in the U.S. in 2017, representing approximately 20 percent of all new cancers in men. While survival rates are high, radiation-induced erectile dysfunction (ED) is a common and lingering side effect associated with prostate radiotherapy. Nearly half of all men undergoing radiation treatment for prostate cancer will experience some level of ED.

Data presented included the results of nonclinical studies that were conducted at UMSOM. These studies demonstrated the potential of BIO 300 to both mitigate radiation-induced ED and also to improve the effectiveness of radiation therapy to kill tumors. “These compelling results show the promise of BIO 300 to enhance a prostate cancer patient’s quality of life, while also directly impacting the ability of radiation therapy to kill the tumor,” said Vujaskovic. “If this result can be translated to the clinical treatment of prostate cancer, it would represent a breakthrough in prostate cancer treatment outcomes.”

At present, there are no U.S. Food and Drug Administration (FDA)-approved drugs to mitigate radiation-induced ED. “BIO 300’s potential to enhance radiation’s killing effect on the tumor while reducing treatment-related side effects is unparalleled,” said Kaytor. “These findings support the advancement of BIO 300 into a human efficacy study, which is anticipated to begin in 2018.”

BIO 300 is in development for prevention and mitigation of toxicities associated with radiation exposure for the treatment of multiple cancers and is currently in a Phase Ib/IIa clinical trial in patients with non-small cell lung cancer who are receiving chemoradiotherapy.

For more information: www.humaneticscorp.com


Related Content

Feature | ASTRO | Christine Book

The Imaging Technology News (ITN) editorial team is pleased to present the second portion of the American Society for ...

Time January 13, 2023
arrow
News | Proton Therapy

January 13, 2023 — RaySearch Laboratories AB announces that The Ohio State University Comprehensive Cancer Center - ...

Time January 13, 2023
arrow
News | Proton Therapy

January 9, 2023 — RaySearch Laboratories AB announced that CGN Medical Technologies has in December 2002 placed an order ...

Time January 08, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As 2022 comes to a close, the Imaging Technology News team takes a look at the year's most viewed content. Here is a ...

Time January 02, 2023
arrow
News | Linear Accelerators

December 30, 2022 — A milestone was reached in radiation therapy last week as the first patients completed their full ...

Time December 30, 2022
arrow
News | Breast Imaging

December 29, 2022 — Anthracyclines are a class of chemotherapies effective in treating many forms of cancer, including ...

Time December 29, 2022
arrow
News | Radiation Therapy

December 22, 2022 — Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation ...

Time December 22, 2022
arrow
News | Digital Pathology

December 22, 2022 — Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, today announced the live ...

Time December 22, 2022
arrow
News | Lung Imaging

December 21, 2022 — Surgery, especially surgery to remove cancerous tumors, relies on a range of tools and techniques as ...

Time December 21, 2022
arrow
News | ASTRO

December 20, 2022 — The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board ...

Time December 20, 2022
arrow
Subscribe Now